1
|
El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol 2024; 35:381-391. [PMID: 38151184 DOI: 10.1016/j.annonc.2023.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 12/07/2023] [Accepted: 12/11/2023] [Indexed: 12/29/2023] Open
Abstract
BACKGROUND Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. PATIENTS AND METHODS Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator as per RECIST version 1.1 (dose expansion). RESULTS Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR as per BICR was 20% [95% confidence interval (CI) 12% to 30%] and 14% (95% CI 9% to 21%) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death-ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6 months) and 15.1 months (95% CI 13.0-18.2 months) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced groups; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% of patients in the sorafenib-naive and sorafenib-experienced groups, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. CONCLUSION With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC.
Collapse
Affiliation(s)
- A B El-Khoueiry
- Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, USA.
| | - J Trojan
- Department of Medicine, Goethe University Hospital and Cancer Center, Frankfurt, Germany
| | - T Meyer
- Department of Oncology, Royal Free Hospital, London, UK
| | - T Yau
- Department of Medicine, University of Hong Kong, Hong Kong, China
| | - I Melero
- Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
| | - C Hsu
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - S-P Choo
- Division of Medical Oncology, National Cancer Center and Curie Oncology, Singapore, Republic of Singapore
| | - Y-K Kang
- Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea
| | - W Yeo
- Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China
| | - A Chopra
- Department of Medical Oncology, Johns Hopkins Singapore International Medical Centre, Singapore, Republic of Singapore
| | - S Soleymani
- Global Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Yao
- Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Neely
- Translational Medicine, Bristol Myers Squibb, Princeton, USA
| | - M Tschaika
- Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA
| | - T H Welling
- Perlmutter Cancer Center and Department of Surgery, NYU Langone Health, New York, USA
| | - B Sangro
- Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
| |
Collapse
|
2
|
Yau T, Rimmer SN, Taylor S. Can’t see, can’t climb a tree, can’t defecate pain free: reactive arthritis due to chlamydial proctitis. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00326-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
3
|
Frost KJ, Hamilton RA, Yau T, Urch J. Research capability and aspirations of antimicrobial pharmacists: survey of UKCPA pin membership. International Journal of Pharmacy Practice 2022. [DOI: 10.1093/ijpp/riac089.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Abstract
Introduction
The United Kingdom Clinical Pharmacist Association Pharmacy Infection Network (UKCPA PIN) is the community of pharmacy professionals with an interest or specialism in infection management. As we come out of the Covid-19 pandemic, it is important for the leadership of UKCPA PIN to understand the current need and wishes of the community.
Aim
This study aimed to explore infection specialist pharmacy professionals about their research activity, experience, and perceived barriers to greater research activity.
Methods
An online, anonymised survey, consisting of closed and free-type open questions, was circulated to UKCPA PIN members for completion in September and October 2021 using the Google Forms platform. The questionnaire was developed and piloted amongst members of UKCPA PIN committee to identify current research activity and barriers. Responses were downloaded and underwent descriptive analysis with Microsoft Excel. This work was deemed a service evaluation and therefore did not require ethics approval.
Results
There were 38 responses were received from pharmacists in all 7 NHS England regions, Scotland, and Wales (6% of UKCPA PIN forum members). Pharmacy technicians were invited to participate but none did so. 13 (34%) described themselves as being actively involved in research, 13 (34%) described themselves as having done research in the past, 8 (21%) described themselves as not having the opportunity to develop research capabilities. 27 (71%) respondents had completed a postgraduate diploma, 8 (21%) had completed MSc or equivalent, 6 (16%) had completed a PhD or equivalent, 11 (29%) were Good Clinical Practice accredited and 10 (26%) had undertaken local research training. 6 (16%) were consultant pharmacists or accredited by the Royal Pharmaceutical Society as being consultant-ready, 10 (27%) were building a consultant portfolio and 15 (39%) were aspiring to build a consultant portfolio in the future. Of the 28% that were building a consultant portfolio, 6 were confident that they were already meeting the research outcomes and 4 were not. Antimicrobial pharmacists were most frequently wanting to undertake research in the areas of antimicrobial stewardship (11, 29%), antifungal stewardship (5, 13%) and allergies/penicillin delabelling (5, 13%). The greatest barriers identified were lack of time/funding (27, 71% agreed significant barrier), lack of funding for costs of undertaking research (17, 45%), lack of support with research methods (9, 24%) and lack of support with dissemination of research (9, 24%). A number of potential support options were proposed to respondents, with “Signposting resources to help you write research protocols” and “A repository of in progress antimicrobial research in the UK” being the most popular (19 and 17 respondents, respectively, described as very useful).
Discussion/Conclusion
There is a significant interest in research amongst antimicrobial pharmacists and scope for enhancing the contribution of pharmacists to research around antimicrobials and infectious disease. A limitation of this study was the small sample size; however, the themes provide important information for UKCPA PIN to provide support for its members.
Collapse
Affiliation(s)
- K J Frost
- Airedale NHS Foundation Trust
- UKCPA PIN Committee
| | - R A Hamilton
- University of Leicester
- Kettering General Hospital NHS Foundation Trust
| | - T Yau
- St George’s University Hospitals NHS Foundation Trust
| | - J Urch
- Great Western Hospitals NHS Foundation Trust
| |
Collapse
|
4
|
Oakley R, Trinh H, Yau T, Khorshid S, Lonsdale D. Improving adherence to and effectiveness of a vancomycin continuous infusion protocol, a pilot quality improvement project. International Journal of Pharmacy Practice 2022. [DOI: 10.1093/ijpp/riac089.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Abstract
Introduction
Vancomycin treats serious Gram-positive infections such as methicillin-resistant Staphylococcus aureus. In St George’s University Hospital’s (SGH) intensive care unit (ICU) settings, vancomycin is administered by continuous infusion. Steady-state serum concentrations are measured daily with a 20-25 mg/L target. Non-therapeutic concentrations are associated with adverse drug reactions/prolonged length of stay.1 A SGH service-evaluation conducted across all three ICUs, revealed variable adherence to/effectiveness of its vancomycin prescribing/administration/monitoring protocol.2 Consequently, multifaceted interventions were devised using the Institute-for-Healthcare-Improvement’s model Plan-Do-Study-Act (PDSA) cycles and piloted on General ICU (GICU).
Aim
(1) To improve adherence to/effectiveness of the vancomycin protocol. (2) To ascertain administration accuracy of paper-fluid-balance-charts compared to the electronic-prescribing-and-medicines-administration (ePMA) system to assist with identifying per protocol treated patients.
Methods
PDSA Cycle-1 was conducted over a 9-month period (09/2021-05/2021) in which a mix of system/person-focused interventions were implemented. Protocol dosing2 was revised, introducing a >90kg patient 2g loading dose, renal-function category revision and increased maintenance dose for creatinine clearance (CLCR) >90ml/min. Protocol accessibility was increased via integration into an ePMA prescribing interface, plus CliniBee/Microguide apps. Educational slides on relevant protocol aspects were incorporated into medical/nursing induction training. Data relating to vancomycin prescribing/administration/monitoring for all non-renal replacement patients was extracted retrospectively from the ePMA system between 09/2021-05/2022. This data was compared to baseline GICU data (07/2020-07/2021).2 The project and associated interventions were approved by Trust Clinical Governance and Audit Teams. Data was collected by pharmacists directly involved in patient’s care and stored/analysed on the Trust’s secure server in line with Data Protection Act principles. Due to local generalisability, ethics approval wasn’t required.
Results
Compared to baseline, the proportion of patients receiving per protocol prescribing/administration of loading/maintenance doses with daily monitoring, nearly doubled (39% (7/18) to 68% (15/22)). 48-hour vancomycin serum concentrations in all patients increased therapeutically by 21% (3/9 to 7/13). In per protocol treated patients, concentrations increased 15% (2/7 to 4/9) therapeutically, decreased 21% (3/7 to 2/9) supra-therapeutically and increased 4% (2/7 to 3/9) sub-therapeutically. Supra-therapeutic concentrations were associated with CLCR<50ml/min. Sub-therapeutic concentrations were associated with CLCR>90ml/min and obesity. Compared to the ePMA system, there was 36% (8/22) less paper-fluid-balance-charts recording both loading/maintenance doses. Maintenance dose administration times in 9% (2/22) of cases differed by >60 minutes.
Discussion/Conclusion
Staff-turnover periods were associated with decreased protocol compliance. Observations suggest further education is required around prescribing/administration of standardised infusion bags for maintenance dosing. Pharmacist integration into daily Microbiology ward rounds may increase protocol compliance. Higher 20mg/kg loading doses for obese patients and maintenance dose revision should be considered to reduce non-therapeutic concentrations.3 Limitations include heterogenous/small sample sizes due to data paucity and vancomycin requirement. This can be addressed by involving all ICU’s in PDSA Cycle-2. Due to disparities, both the ePMA system and paper-fluid-balance-charts should be used to identify protocol adherence. Utilisation of digital-infusion-pump data to quantify administration accuracy may offer a promising solution. Piloted multifaceted interventions were successful at improving adherence to/effectiveness of the vancomycin protocol. Findings have informed further interventions and data capture methods for PDSA Cycle-2 implementation across all ICUs.
References
1. Perin N, Roger C, Marin G, Molinari N, Evrard A, Lavigne J et al. Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics. 2020;9(11):793. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698174/
2. Oakley R, Bakrania P, Yau T, Standing J, Lonsdale D. P37 Variable adherence to and effectiveness of a vancomycin continuous infusion protocol within ICUs at a London tertiary-care hospital: a single-centre retrospective service evaluation. JAC-Antimicrobial Resistance. 2022;4(Supplement_1). Available from: https://academic.oup.com/jacamr/issue/4/Supplement_1
3. Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020;77(11):835-864. Available from: https://academic.oup.com/ajhp/article/77/11/835/5810200?login=false
Collapse
Affiliation(s)
- R Oakley
- St George’s University Hospitals NHS Foundation Trust
| | - H Trinh
- St George’s University Hospitals NHS Foundation Trust
| | - T Yau
- St George’s University Hospitals NHS Foundation Trust
| | - S Khorshid
- St George’s University Hospitals NHS Foundation Trust
| | - D Lonsdale
- St George’s University Hospitals NHS Foundation Trust
| |
Collapse
|
5
|
Chan S, Kudo M, Sangro B, Kelley R, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Cheng AL, Azevedo S, Reig Monzon M, Assenat E, Yarchoan M, He A, Makowsky M, Gupta C, Negro A, Abou-Alfa G. 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
6
|
Chan L, Kudo M, Sangro B, Kelley R, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Cheng AL, Azevedo S, Reig Monzon M, Assenat E, Yarchoan M, He A, Makowsky M, Ran D, Negro A, Abou-Alfa G. 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Edeline J, Finn R, Bouattour M, Cheng AL, Chan S, Yau T, Garrido M, Knox J, Daniele B, Breder V, Lim H, Ogasawara S, Odeleye-Ajakaye A, Martinez-Forero I, Siegel A, Merle P. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Melero I, Yau T, Kang Y, Kim T, Santoro A, Sangro B, Kudo M, Hou M, Matilla A, Tovoli F, Knox J, He A, El-Rayes B, Acosta-Rivera M, Lim H, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry A. SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Pi L, Wang V, Aleksova N, Luk A, Posada JGD, Patriquin C, Dhamko H, Alvarez J, Yau T, Morris I, Hosseini-Moghaddam S, McDonald M, Cserti-Gazdewich C, Moayedi Y. A Real Circuit Breaker: Hyperhemolysis Syndrome Related to the VA-ECMO Circuit? J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
10
|
Kelley R, Yau T, Cheng AL, Kaseb A, Qin S, Zhu A, Chan S, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Gomez Rangel J, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Rimassa L. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2021.10.008] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
11
|
Stoklosa K, Mazine A, Forgie K, Brown A, Hage A, Ridwan K, Eikelboom R, Laurin C, Clarizia N, Luc J, Yau T. OPENING THE CARMS BLACK BOX: THE IMPORTANCE OF VARIOUS ASPECTS OF THE CARMS APPLICATION FOR CARDIAC SURGERY APPLICANTS. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Bishnoi S, Cosman R, Moore M, Eek R, Mant A, Zielinski R, Chan L, Ma Y, Zhang Q, Yau T, Aghmesheh M, Tse A. 981P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Vogel A, Zhu A, Cheng A, Yau T, Zhou J, Kim E, Malhotra U, Siegel A, Kudo M. Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Sangro B, Harding J, Johnson M, Palmer D, Edeline J, Abou-Alfa G, Cheng A, Decaens T, El-Khoueiry A, Finn R, Galle P, Park J, Yau T, Begic D, Shen Y, Neely J, Sama A, Kudo M. Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
15
|
Dai M, Feng Y, Chen S, Masuda N, Sangai T, Yau T, Kwong A, Ngan R, Yap Y, Ang P, Ow S, Lee K, Kim S, Chung H, Keyvanjah K, Bebchuk J, Chen MC. 46O Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Vogel A, Merle P, Verslype C, Finn R, Zhu A, Cheng AL, Chan S, Yau T, Ryoo BY, Wei Z, Malhotra U, Siegel A, Kudo M. 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
17
|
Yau T, Hsu C, Kang Y, Kim T, Hou M, Lim H, Chao Y, Kim Y, Ikeda M, Choo S, Neely J, Shen Y, Tschaika M, Kudo M. O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Sangro B, Park J, Finn R, Cheng A, Mathurin P, Edeline J, Kudo M, Han K, Harding J, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo S, Kelley R, Begic D, Chen G, Neely J, Tschaika M, Yau T. LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.078] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
19
|
Chao Y, Maglakelidze M, Bulat L, Yau T, Tanasanvimon S, Charoentum C, Arpornwirat W, Maneechavakajorn J, Dechaphunkul A, Ungtrakul T, Yen CJ, Bai LY, Chou WC, Weidermann U, Garner-Spitzer E, Ede N, Chong L, Good A. A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Yau T, Rimassa L, Cheng AL, Park JW, Braiteh F, Chaudhry A, Benzaghou F, Thuluvath P, Hazra S, Milwee S, Tan B, Sinha R, Kayali Z, Zhu A, Kelley R. Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Yau T, Meyer T, Kelley R, Mangeshkar M, Cheng AL, El-Khoueiry A, Abou-Alfa G. Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Wiedermann U, Garner-Spitzer E, Chao Y, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen C, Yau T, Maglakelidzde M, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Zielinski C, Chong L, Ede N, Good A. Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Merle P, Kulkarni A, Ryoo BY, Cheng AL, Kudo M, Bouattour M, Lim H, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan S, Daniele B, Norquist J, Chen E, Siegel A, Zhu A, Finn R. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Yau T, Park J, Finn R, Cheng AL, Mathurin P, Edeline J, Kudo M, Han KH, Harding J, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo S, Kelley R, Begic D, Chen G, Neely J, Anderson J, Sangro B. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.029] [Citation(s) in RCA: 433] [Impact Index Per Article: 86.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
|
25
|
Finn R, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan S, Knox J, Daniele B, Ebbinghaus S, Chen E, Siegel A, Zhu A, Cheng AL. Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Maglakelidze M, Yau T, Bulat I, Yen C, Chao Y, Bai L, Good A, Ede N, Chong L, Tanasanvimon S, Charoetum C, Loong H, Lausoontornsiri W, Arpornwirat W, Maneechavakajon J, Ungtrakul T, Chou W. A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz157.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Yu F, Alvarez J, Ribeiro R, Adamson M, Amin F, Degen M, Foroutan F, Posada JD, Yau T, Cusimano R, Billia F, Alba C, Badiwala M, Rao V. Does Left Atrial Appendage Occlusion in LVAD Patients Impact Outcomes: A Single Centre Study. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
28
|
Yau T, Merle P, Rimassa L, Ryoo BY, Cicin I, Harris W, Banu E, Sarker D, Tan B, van Vlierberghe H, Sen S, Love C, Cheng AL, Meyer T, Kelley R, Abou-Alfa G. Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Yau T, Cheng AL, Meyer T, Ryoo BY, Park JW, Klümpen HJ, Lim H, Kim S, Knox J, Patel M, El-Khoueiry A, Kelley R, Abou-Alfa G. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.087] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
30
|
Adamson M, Vanin Pinto Ribeiro R, Alvarez J, Yu F, Yau T, Cusimano R, Ross H, Delgado D, Rao V, Badiwala M. RECIPIENT PROFILE AND OUTCOMES OVER 30 YEARS OF A SINGLE QUATERNARY HOSPITAL'S HEART TRANSPLANT PROGRAM. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
31
|
Alvarez J, Vanin Pinto Ribeiro R, Yu F, Adamson M, Yau T, Cusimano R, Ross H, Rao V, Badiwala M. CHANGING DONOR PROFILE OVER 30 YEARS OF A HEART TRANSPLANT PROGRAM. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
32
|
Der Sarkissian S, Sauvé J, Larose E, Stevens L, Yau T, Prieto I, Basile F, Mansour S, Roy D, Noiseux N. Identification of differential expression phenotypes of CD133 + stem cells in acute and chronic myocardial infarct patients and specific expression pathways underpinning therapeutic responsiveness in regenerative therapy. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
33
|
Alvarez J, Ribeiro R, Yu F, Yau T, Cusimano R, Ross H, Rao V, Badiwala M. Changing Donor Profile Over 30 Years of a Heart Transplant Program. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
34
|
Chiu J, Leung R, Sze H, Teo P, Choi P, Lam TC, Yau T, Cheng P, Cheung FY, Cheung P. Real world data on use of palbociclib in hormone-receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Choo S, Yau T, Hsu C, Kang YK, Hou MM, Yeo W, Numata K, Chopra A, Baakili A, Dela Cruz C, Zhao H, Kudo M. Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Ribeiro R, Alvarez J, Yu F, Alba A, Yau T, Cusimano R, Billia F, Rao V, Badiwala M. TRANSPLANT OUTCOMES IN PATIENTS BRIDGED WITH LVAD THERAPY AT TORONTO GENERAL HOSPITAL. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
37
|
Alvarez J, Duero Posada J, Moayedi Y, Alhussein M, Runeckles K, Ross H, Alba A, Billia F, Badiwala M, Cusimano R, Yau T, Rao V. CLINICAL DIFFERENCES BETWEEN CONTEMPORARY CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICES: A SINGLE CENTER COMPARISON BETWEEN HEARTWARE, HEARTMATE II AND HEARTMATE 3. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
38
|
Kim R, Sarker D, Macarulla T, Yau T, Choo S, Meyer T, Hollebecque A, Whisenant J, Sung M, Yoon JH, Lim H, Zhu A, Park JW, Faivre S, Mazzaferro V, Shi H, Schmidt-Kittler O, Clifford C, Wolf B, Kang YK. Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Abou-Alfa G, Yoon J, Modiano M, Ryoo B, Yau T, Freilich B, Knox J, Ly M, Ahmad H, Gahir S, Niforos D, Kowalski M, Kelley R. An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32646-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
40
|
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo S, Trojan J, Meyer T, WellingIII T, Yeo W, Chopra A, Anderson J, DelaCruz C, Lang L, Neely J, El-Khoueiry A. 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw582] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo SP, Trojan J, Meyer T, Welling T, Yeo W, Chopra A, Anderson J, De Cruz C, Lang L, Neely J, El-Khoueiry A. Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Rocha R, Roche S, Rao V, Yau T, Billia P, Hickey E. SUBAORTIC RIGHT VENTRICLE TO SYSTEMIC SUPPORT WITH IMPLANTABLE VENTRICULAR ASSIST DEVICE IN PATIENTS WITH COMPLEX CONGENITAL HEART DISEASE. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
43
|
Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan ZZ, Masood N, Srimuninnimit V, Yau T, Beier F, Chatterjee S, Lim R. O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Yau T, Chiu J, Cheung TT. What determines treatment success and future perspectives? Postgrad Med J 2016; 92:123-4. [PMID: 26917775 DOI: 10.1136/postgradmedj-2016-134018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- T Yau
- Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
| | - J Chiu
- Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
| | - T T Cheung
- Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong
| |
Collapse
|
45
|
Ng L, Wan T, Chow A, Man J, Iyer D, Leung WK, Yau T, Lo O, Foo D, Poon J, Law WL, Pang R. 37P Serum microRNAs as potential biomarker for screening colorectal cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv518.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Chiu J, Leung R, Tang V, Cheuk I, Lo J, Wong H, Kwok G, Suen D, Yau T, Kwong A. 71P Evolution of neoadjuvant chemotherapy (NAC) in locally advanced HER2-positive breast cancer over 10 years in Hong Kong. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Noiseux N, Mansour S, Weisel R, Stevens L, Tsang K, Larose E, Li S, Spiller N, Vu M, Crean A, Roy D, Prieto I, Li R, Yau T. THE IMPACT-CABG TRIAL: A CANADIAN RCT OF CD133+ STEM CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
48
|
Kawajiri H, Goldraich L, Foroutan F, Ghashghai A, Lazarte J, Grosman-Rimon L, Stansfield W, Badiwala M, Cusimano R, Yau T, Ross H, Billia F, Rao V. REQUIRING HIGH PUMP SPEED MAY PREDICT LONG-TERM MORTALITY AFTER CF-VAD INSERTION. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
49
|
Steinbach S, Yau T, Ouzounian M, Chandy M, Abdel-Qadir H, Waddell T, Husain M. MODELING TYPE II DIABETES-ASSOCIATED VASCULOPATHIES WITH SKIN-DERIVED PRECURSORS. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26:2457-63. [PMID: 26386123 DOI: 10.1093/annonc/mdv388] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Accepted: 09/10/2015] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS Patients with HCC and Child-Pugh Class A who progressed on or were intolerant to one prior antiangiogenic therapy were stratified by tumour invasion (presence/absence of extrahepatic spread and/or vascular invasion) and region (Asian/non-Asian) and randomized (2:1) to axitinib/BSC (starting dose 5 mg twice-daily) or placebo/BSC. The primary end point was overall survival (OS). RESULTS The estimated hazard ratio for OS was 0.907 [95% confidence interval (CI) 0.646-1.274; one-sided stratified P = 0.287] for axitinib/BSC (n = 134) versus placebo/BSC (n = 68), with the median (95% CI) of 12.7 (10.2-14.9) versus 9.7 (5.9-11.8) months, respectively. Results of prespecified subgroup analyses in Asian versus non-Asian patients or presence versus absence of tumour invasion were consistent with the overall population. Improvements favouring axitinib/BSC (P < 0.01) were observed in secondary efficacy end point analyses [progression-free survival (PFS), time to tumour progression (TTP), and clinical benefit rate (CBR)], and were retained among Asian patients in the prespecified subgroup analyses. Overall response rate did not differ significantly between treatments and patient-reported outcomes favoured placebo/BSC. Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). Baseline serum analyses identified potential new prognostic (interleukin-6, E-selectin, interleukin-8, angiopoietin-2, migration inhibitory factor, and c-MET) or predictive (E-selectin and stromal-derived factor-1) factors for survival. CONCLUSIONS Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. However, axitinib/BSC resulted in significantly longer PFS and TTP and higher CBR, with acceptable toxicity in patients with advanced HCC. TRIAL REGISTRATION ClinicalTrials.gov, NCT01210495.
Collapse
Affiliation(s)
- Y-K Kang
- Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea
| | - T Yau
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
| | - J-W Park
- National Cancer Center/Center for Liver Cancer, Goyang-si
| | - H Y Lim
- Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea
| | - T-Y Lee
- Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital, Taichung, Taiwan
| | - S Obi
- Department of Hepatology, Sasaki Foundation Kyoundo Hospital, Tokyo, Japan
| | - S L Chan
- State Key Laboratory in Oncology of South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong
| | - Sk Qin
- Nanjing Bayi Hospital, Nanjing, China
| | - R D Kim
- H. Lee Moffitt Cancer Center, Tampa
| | | | | | | | | | | | | | - M Kudo
- Department of Gastroenterology and Hepatology, Kinki University Hospital, Osaka, Japan
| |
Collapse
|